Literature DB >> 29247995

Overview of the IL-1 family in innate inflammation and acquired immunity.

Charles A Dinarello1,2.   

Abstract

The interleukin-1 (IL-1) family of cytokines and receptors is unique in immunology because the IL-1 family and Toll-like receptor (TLR) families share similar functions. More than any other cytokine family, the IL-1 family is primarily associated with innate immunity. More than 95% of living organisms use innate immune mechanisms for survival whereas less than 5% depend on T- and B-cell functions. Innate immunity is manifested by inflammation, which can function as a mechanism of host defense but when uncontrolled is detrimental to survival. Each member of the IL-1 receptor and TLR family contains the cytoplasmic Toll-IL-1-Receptor (TIR) domain. The 50 amino acid TIR domains are highly homologous with the Toll protein in Drosophila. The TIR domain is nearly the same and present in each TLR and each IL-1 receptor family. Whereas IL-1 family cytokine members trigger innate inflammation via IL-1 family of receptors, TLRs trigger inflammation via bacteria, microbial products, viruses, nucleic acids, and damage-associated molecular patterns (DAMPs). In fact, IL-1 family member IL-1a and IL-33 also function as DAMPs. Although the inflammatory properties of the IL-1 family dominate in innate immunity, IL-1 family member can play a role in acquired immunity. This overview is a condensed update of the IL-1 family of cytokines and receptors.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acquired immunity; cytokines; host defense; immunity; inflammation; innate immunity

Mesh:

Substances:

Year:  2018        PMID: 29247995      PMCID: PMC5756628          DOI: 10.1111/imr.12621

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  258 in total

1.  Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease.

Authors:  Othmar Ludwiczek; Arthur Kaser; Daniela Novick; Charles A Dinarello; Menachem Rubinstein; Wolfgang Vogel; Herbert Tilg
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

2.  Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.

Authors:  Jesper F Højen; Thomas A Rasmussen; Karen Lise D Andersen; Anni A Winckelmann; Rune R Laursen; Jesper D Gunst; Holger J Møller; Mayumi Fujita; Lars Østergaard; Ole S Søgaard; Charles A Dinarello; Martin Tolstrup
Journal:  Mol Med       Date:  2015-04-14       Impact factor: 6.354

Review 3.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

4.  Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha.

Authors:  Y Kobayashi; K Yamamoto; T Saido; H Kawasaki; J J Oppenheim; K Matsushima
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

5.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

6.  Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta.

Authors:  B J Pomerantz; L L Reznikov; A H Harken; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

7.  IL-37 requires IL-18Rα and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice.

Authors:  L Lunding; S Webering; C Vock; A Schröder; D Raedler; B Schaub; H Fehrenbach; M Wegmann
Journal:  Allergy       Date:  2015-01-26       Impact factor: 13.146

8.  Acute renal failure in cirrhotic patients with severe sepsis: value of urinary interleukin-18.

Authors:  Ming-Hung Tsai; Yung-Chang Chen; Chih-Wei Yang; Chang-Chi Jenq; Ji-Tseng Fang; Jau-Min Lien; Cheng-Chieh Hung; Hsu-Huei Weng; Cheng-Shyong Wu; Yun-Shing Peng; Chien-Heng Shen; Shui-Yi Tung; Ya-Chung Tian
Journal:  J Gastroenterol Hepatol       Date:  2013-01       Impact factor: 4.029

9.  A urine inhibitor of interleukin 1 activity that blocks ligand binding.

Authors:  P Seckinger; J W Lowenthal; K Williamson; J M Dayer; H R MacDonald
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

10.  A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.

Authors:  Caroline Sutton; Corinna Brereton; Brian Keogh; Kingston H G Mills; Ed C Lavelle
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

View more
  381 in total

1.  Extended subsite profiling of the pyroptosis effector protein gasdermin D reveals a region recognized by inflammatory caspase-11.

Authors:  Betsaida Bibo-Verdugo; Scott J Snipas; Sonia Kolt; Marcin Poreba; Guy S Salvesen
Journal:  J Biol Chem       Date:  2020-06-18       Impact factor: 5.157

2.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.

Authors:  Jan Tavernier; Sarah Gerlo; Bram Van Den Eeckhout; Lien Van Hoecke; Elianne Burg; Sandra Van Lint; Frank Peelman; Niko Kley; Gilles Uzé; Xavier Saelens
Journal:  NPJ Vaccines       Date:  2020-07-23       Impact factor: 7.344

4.  Cutting Edge: IL-1R1 Mediates Host Resistance to Mycobacterium tuberculosis by Trans-Protection of Infected Cells.

Authors:  Andrea C Bohrer; Claire Tocheny; Maike Assmann; Vitaly V Ganusov; Katrin D Mayer-Barber
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

5.  How Can Interleukin-1 Receptor Antagonist Modulate Distinct Cell Death Pathways?

Authors:  Angelo Spinello; Elena Vecile; Antonio Abbate; Aldo Dobrina; Alessandra Magistrato
Journal:  J Chem Inf Model       Date:  2019-01-10       Impact factor: 4.956

Review 6.  Role of meprin metalloproteinases in cytokine processing and inflammation.

Authors:  Christian Herzog; Randy S Haun; Gur P Kaushal
Journal:  Cytokine       Date:  2018-12-20       Impact factor: 3.861

7.  Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice.

Authors:  Michael Y T Chow; Rachel Yoon Kyung Chang; Mengyu Li; Yuncheng Wang; Yu Lin; Sandra Morales; Andrew J McLachlan; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

8.  Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.

Authors:  Surendra K Shukla; Spas D Markov; Kuldeep S Attri; Enza Vernucci; Ryan J King; Aneesha Dasgupta; Paul M Grandgenett; Michael A Hollingsworth; Pankaj K Singh; Fang Yu; Kamiya Mehla
Journal:  Cancer Lett       Date:  2020-04-25       Impact factor: 8.679

Review 9.  IL-1 Superfamily Members and Periodontal Diseases.

Authors:  E Papathanasiou; P Conti; F Carinci; D Lauritano; T C Theoharides
Journal:  J Dent Res       Date:  2020-08-06       Impact factor: 6.116

10.  IL-36R signaling integrates innate and adaptive immune-mediated protection against enteropathogenic bacteria.

Authors:  Vu L Ngo; Hirohito Abo; Michal Kuczma; Edyta Szurek; Nora Moore; Oscar Medina-Contreras; Asma Nusrat; Didier Merlin; Andrew T Gewirtz; Leszek Ignatowicz; Timothy L Denning
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.